Who are Placebo-Repaglinide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ISL, Comparator: glipizide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-repaglinide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Placebo-Repaglinide — Competitive Intelligence Brief

Placebo-Repaglinide (Placebo-Repaglinide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Meglitinide (rapid-acting insulin secretagogue). Area: Diabetes.

marketed Meglitinide (rapid-acting insulin secretagogue) ATP-sensitive potassium channel / Sulfonylurea receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo-Repaglinide (Placebo-Repaglinide) — Steno Diabetes Center Copenhagen. Repaglinide is a meglitinide that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo-Repaglinide TARGET	Placebo-Repaglinide	Steno Diabetes Center Copenhagen	marketed	Meglitinide (rapid-acting insulin secretagogue)	ATP-sensitive potassium channel / Sulfonylurea receptor
ISL	ISL	Merck Sharp & Dohme LLC	marketed	Meglitinide (rapid-acting insulin secretagogue)	ATP-sensitive potassium channel (KATP channel)
Comparator: glipizide	Comparator: glipizide	Merck Sharp & Dohme LLC	phase 3	Meglitinide (rapid-acting insulin secretagogue)	ATP-sensitive potassium channel (KATP channel) / Sulfonylurea receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Meglitinide (rapid-acting insulin secretagogue) class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Steno Diabetes Center Copenhagen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo-Repaglinide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-repaglinide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab